

# Kenneth Cusi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6525105/publications.pdf>

Version: 2024-02-01

154  
papers

27,662  
citations

15880

67  
h-index

10399

144  
g-index

157  
all docs

157  
docs citations

157  
times ranked

24210  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 29-38.	1.8	82
2	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 154-159.	2.2	5
3	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
4	Reply. <i>Gastroenterology</i> , 2022, , .	0.6	0
5	A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3076-e3077.	1.8	1
6	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. <i>Diabetes Care</i> , 2022, 45, 1007-1012.	4.3	4
7	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31
8	A global view of the interplay between non-alcoholic fatty liver disease and diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 284-296.	5.5	232
9	Response to: "Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?" <i>Obesity</i> , 2022, , .	1.5	0
10	JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. <i>Journal of Clinical Lipidology</i> , 2022, 16, 115-127.	0.6	0
11	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 393-406.	5.5	155
12	Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores. <i>JMIR Medical Informatics</i> , 2022, 10, e36997.	1.3	5
13	Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. <i>Obesity</i> , 2022, 30, 1231-1238.	1.5	11
14	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	1.1	323
15	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	8.2	174
16	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
17	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. <i>Hepatology Communications</i> , 2021, 5, 938-946.	2.0	21
18	Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. <i>Nutrition Research</i> , 2021, 88, 34-43.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1344-1352.	4.3	21
20	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. <i>European Journal of Endocrinology</i> , 2021, 184, 587-596.	1.9	12
21	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	8.2	72
22	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4360-e4371.	1.8	6
23	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0251449.	1.1	11
24	Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2021;44:1344-1352. <i>Diabetes Care</i> , 2021, 44, e167-e167.	4.3	0
25	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
26	Saroglitazar, a PPAR $\alpha$ / $\beta$ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	3.6	163
27	PPAR $\alpha$ -induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021, 41, 2659-2670.	1.9	51
28	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7
29	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
30	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	3.7	26
31	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25
32	Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. <i>Obesity</i> , 2021, 29, 1950-1960.	1.5	70
33	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.6	229
34	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	4.3	173
35	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1472-1480.	1.9	10
36	Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. <i>Cell Reports Medicine</i> , 2021, 2, 100474.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 401-410.	1.8	40
38	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. <i>Journal of Hepatology</i> , 2020, 72, 613-626.	1.8	143
39	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 290-297.	4.3	113
40	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. <i>Journal of Investigative Medicine</i> , 2020, 68, 743-747.	0.7	13
41	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
42	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 674-690.	0.6	72
43	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Diabetes Reports</i> , 2020, 20, 59.	1.7	39
44	Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. <i>Current Opinion in Lipidology</i> , 2020, 31, 364-366.	1.2	10
45	A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. <i>Liver International</i> , 2020, 40, 82-88.	1.9	36
46	Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 275-279.	4.3	49
47	Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?. <i>American Journal of Medicine</i> , 2020, 133, 536-543.	0.6	43
48	1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes</i> , 2020, 69, 1461-P.	0.3	1
49	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
50	Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. <i>Journal of Diabetes</i> , 2019, 11, 223-231.	0.8	26
51	Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. <i>PLoS ONE</i> , 2019, 14, e0219855.	1.1	7
52	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. <i>JHEP Reports</i> , 2019, 1, 312-328.	2.6	251
53	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1348-1351.	4.3	37
54	Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5249-5250.	1.8	2

#	ARTICLE	IF	CITATIONS
55	Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities. <i>Obesity</i> , 2019, 27, 1099-1106.	1.5	8
56	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2019, 42, 1481-1488.	4.3	202
57	Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. <i>Hepatology</i> , 2019, 69, 2318-2322.	3.6	37
58	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3327-3336.	1.8	68
59	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	5.5	566
60	Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial. <i>Experimental Gerontology</i> , 2019, 116, 46-53.	1.2	31
61	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 70, 711-724.	3.6	305
62	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 812-821.	2.2	117
63	Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani <i>et al</i> . ( <i>Thyroid</i> 2018;28:1270-1284). <i>Thyroid</i> , 2019, 29, 452-452.	2.4	4
64	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019, 67, 303-311.	0.7	59
65	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. <i>Journal of Endocrinology</i> , 2019, 241, 293-305.	1.2	25
66	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
67	Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1220-1221.	1.9	6
68	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 558-566.e2.	2.4	154
69	Use of a metabolomic approach to noninvasively diagnose nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1702-1709.	2.2	39
70	Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. <i>Gut</i> , 2018, 67, 1371-1371.	6.1	10
71	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	3.6	4,738
72	Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option. <i>Journal of Investigative Medicine</i> , 2018, 66, 7-10.	0.7	49

#	ARTICLE	IF	CITATIONS
73	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. <i>Journal of Investigative Medicine</i> , 2018, 66, 661-668.	0.7	3
74	Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> , 2018, 41, 187-192.	4.3	37
75	Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. <i>Diabetes Care</i> 2018;41:187-192. <i>Diabetes Care</i> , 2018, 41, e137-e138.	4.3	2
76	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E163-E173.	1.8	50
77	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	1.6	23
78	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the AWARD programme. <i>Diabetic Medicine</i> , 2018, 35, 1434-1439.	1.2	59
79	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2018, , 47-69.	0.0	0
80	Reply to "Statins and non-alcoholic steatohepatitis". <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e3-e5.	1.5	4
81	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	4.3	256
82	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017, 166, 230.	2.0	5
83	Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1630-1634.	2.2	137
84	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 56-61.	1.9	28
85	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2950-2961.	1.8	66
86	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. <i>Hepatology</i> , 2017, 66, 296-297.	3.6	5
87	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 65, 1132-1144.	3.6	191
88	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 250-260.	3.1	228
89	Improved experimental data processing for UHPLC-MS/MS lipidomics applied to nonalcoholic fatty liver disease. <i>Metabolomics</i> , 2017, 13, 1.	1.4	38
90	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. <i>Contemporary Clinical Trials</i> , 2017, 61, 33-38.	0.8	38

#	ARTICLE	IF	CITATIONS
91	Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 444-446.	2.3	0
92	Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. <i>Hepatology</i> , 2017, 65, 4-7.	3.6	25
93	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2016, 165, 305.	2.0	732
94	Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E484-E494.	1.8	126
95	Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. <i>Journal of Investigative Medicine</i> , 2016, 64, 63-68.	0.7	26
96	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 9.	1.3	45
97	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. <i>Diabetologia</i> , 2016, 59, 1112-1120.	2.9	102
98	Prediabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 751-764.	1.2	55
99	Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 765-781.	1.2	107
100	Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 50-58.	2.2	29
101	Diabetes medications improve cardiovascular outcomes. <i>Current Opinion in Lipidology</i> , 2016, 27, 633-635.	1.2	0
102	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1183-1195.	1.5	86
103	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 632-638.	4.3	108
104	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 644-652.	1.8	127
105	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. <i>Liver International</i> , 2015, 35, 2139-2146.	1.9	169
106	Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015, 35, 2341-2342.	1.9	1
107	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2231-2238.	1.8	404
108	Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E311-E319.	1.8	88

#	ARTICLE	IF	CITATIONS
109	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 62, 405-411.	1.8	98
110	The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 61, 153-160.	3.6	156
111	Induction of Mitochondrial Triâ€carboxylic Acid Cycle is Sustained in Mice with Nonalcoholic Steatohepatitis (NASH). <i>FASEB Journal</i> , 2015, 29, 258.4.	0.2	0
112	Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2014, 13, 159-170.	0.4	20
113	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 59, 2178-2187.	3.6	129
114	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 167-174.	1.8	223
115	Healthcare Transition from Pediatric to Adult Medical Homes. <i>Endocrine Practice</i> , 2014, 20, 714-720.	1.1	4
116	The relationship between hepatitis C virus infection and diabetes: Time for a divorce?. <i>Hepatology</i> , 2014, 60, 1121-1123.	3.6	11
117	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> . 2014, 969, 219-223.	1.2	12
118	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. <i>Drugs</i> , 2013, 73, 1-14.	4.9	139
119	The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2013, 13, 329-341.	1.7	101
120	Plasma Branch Chain and Aromatic Amino Acid Levels are Associated with Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). <i>FASEB Journal</i> , 2013, 27, .	0.2	0
121	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Clinical Lipidology</i> , 2012, 7, 471-481.	0.4	23
122	Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD). <i>Diabetes Care</i> , 2012, 35, 873-878.	4.3	214
123	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	0.6	1,486
124	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. <i>Gastroenterology</i> , 2012, 142, 711-725.e6.	0.6	711
125	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1389-1397.	3.6	348
126	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	3.6	2,935



#	ARTICLE	IF	CITATIONS
127	An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2011, 2, 211-225.	1.4	30
128	Unmet Needs in Hispanic/Latino Patients with Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 2011, 124, S2-S9.	0.6	37
129	Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 1090-1099.	1.5	49
130	Insulin sensitizers in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 53, 1404-1405.	3.6	4
131	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 837-845.	3.6	74
132	The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 306-315.	1.7	239
133	Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. <i>Cardiovascular Diabetology</i> , 2010, 9, 9.	2.7	120
134	Pioglitazone in the treatment of NASH: the role of adiponectin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 769-775.	1.9	97
135	Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 829-836.	1.8	143
136	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009, 50, 1087-1093.	3.6	231
137	Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2009, 9, 200-207.	1.7	22
138	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). <i>Annals of Medicine</i> , 2009, 41, 265-278.	1.5	108
139	Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2009, 13, 545-563.	1.0	192
140	Nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 141-149.	1.2	150
141	Chronic Low-Dose Lipid Infusion in Healthy Patients Induces Markers of Endothelial Activation Independent of Its Metabolic Effects. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 141-146.	1.7	21
142	Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1775-E1781.	1.8	89
143	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2007, 47, 565-570.	1.8	73
144	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	0.6	500

#	ARTICLE	IF	CITATIONS
145	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2006, 355, 2297-2307.	13.9	1,584
146	Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 105-114.	2.3	26
147	Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling. <i>Diabetes</i> , 2005, 54, 1640-1648.	0.3	333
148	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 2461-2474.	0.3	447
149	Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2784-2791.	1.8	629
150	Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 462-468.	0.3	109
151	Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. <i>Journal of Clinical Investigation</i> , 2000, 105, 311-320.	3.9	953
152	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4059-4067.	1.8	349
153	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4059-4067.	1.8	285
154	Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM. <i>Diabetes Care</i> , 1995, 18, 843-851.	4.3	68